OncoMatch/Clinical Trials/NCT06506838
Anlotinib Combined With Doxorubicin and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Is NCT06506838 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Anlotinib for soft tissue sarcoma.
Treatment: Anlotinib — Exploring the Efficacy and Safety of Anlotinib Combined with Doxorubicin Monotherapy and Radiotherapy as Neoadjuvant Treatment for Soft Tissue Sarcoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Sarcoma
Disease stage
Grade: g2g3
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: chemotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: angiogenesis inhibitor (sunitinib, sorafenib, imatinib, famitinib, regorafenib)
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Cannot have received: immunotherapy
Exception: eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment
Receipt of any form of anti-tumor treatment within 4 weeks prior to enrollment, including radiotherapy, chemotherapy, molecular targeted therapy (such as angiogenesis inhibitors like sunitinib, sorafenib, imatinib, famitinib, regorafenib), and immunotherapy (eligible if last anti-tumor drug was stopped ≥5 half-lives before enrollment)
Lab requirements
Blood counts
absolute neutrophil count ≥1500/μl, platelet count ≥100,000/μl
Kidney function
creatinine clearance or radioisotope gfr ≥70 ml/min/1.73 m² or serum creatinine within normal limits according to age/gender
Liver function
total bilirubin ≤1.5 × uln, ast or alt <2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06506838 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, chemotherapy, angiogenesis inhibitor disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages